Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial.
Literature
Read More
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press Release
Read More
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
Press Release
Read More
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
Press Release
Read More
Deep phenotyping and spatial immune contexture characterization through a combined multiplex immunofluorescence ( mIF ) approach
Literature
Read More
NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors
Press Release
Read More